Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates

Financial Performance - Exagen Inc. reported a quarterly loss of $0.28 per share, which was better than the Zacks Consensus Estimate of a loss of $0.30, and an improvement from a loss of $0.31 per share a year ago, representing an earnings surprise of 6.67% [1] - The company posted revenues of $12.51 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 7.70%, and down from $13.42 million in the same quarter last year [2] - Over the last four quarters, Exagen has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Exagen shares have increased approximately 49.3% since the beginning of the year, outperforming the S&P 500's gain of 25.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $14 million, and for the current fiscal year, it is -$1.03 on revenues of $57.05 million [7] Industry Outlook - The Medical - Products industry, to which Exagen belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Exagen's stock may be influenced by the overall outlook for the industry [8]